The obesity drug development landscape is moving faster than ever. With more than 150 clinical-stage obesity assets under development and new scientific understanding reshaping how obesity is defined and managed, sponsors face an important question: Are traditional clinical trial endpoints still sufficient to demonstrate meaningful patient benefit?

A recent article in DIA Global Forum, Obesity Drug Development: Time to Revisit Endpoints, Trial Design, and Evidence Generation, explores how regulators, industry leaders, clinicians, and patient advocates are rethinking obesity drug development in response to rapid innovation.

Beyond the Scale: Defining Quality Weight Loss

Historically, obesity clinical trials have relied on body weight and BMI as primary efficacy endpoints. While these measures remain important and familiar to regulators, they may not tell the complete story.

As obesity treatments become more effective, stakeholders are increasingly focused on the quality of weight loss, including changes in body composition, preservation of lean muscle mass, physical function, and overall health outcomes. The article highlights growing interest in understanding whether maintaining muscle and improving mobility may be as clinically meaningful as the total number of pounds lost.

This shift reflects a broader evolution in how obesity is understood as a chronic, systemic disease rather than simply a condition defined by body weight alone. New clinical guidelines and regulatory discussions are encouraging the use of additional measures that better characterize excess adiposity and patient health.

The Endpoint Challenge

While the industry recognizes the importance of evaluating body composition and physical function, significant questions remain.

What level of lean mass loss is clinically meaningful? Which functional assessments should be standardized across trials? How can sponsors balance scientific rigor with operational feasibility?

According to the article, participants in DIA's Executive Roundtable emphasized the need for more evidence to establish meaningful thresholds and validated endpoints. Functional measures such as mobility and muscle strength may provide additional insight into treatment benefit, but regulatory pathways for incorporating these outcomes into labelling claims remain unclear.

For sponsors, this creates both a challenge and an opportunity. The organizations that generate robust evidence linking body composition and functional outcomes to meaningful clinical benefit may help shape the future of obesity drug development.

Why Evidence Generation Matters More Than Ever

The obesity market is becoming increasingly competitive. As more therapies enter development across multiple mechanisms of action, differentiation will depend on more than weight reduction alone.

Sponsors must demonstrate how treatments impact broader patient outcomes, safety profiles, long-term health benefits, and quality of life. This will require thoughtful clinical development strategies that integrate innovative endpoint selection, patient-centric measures, real-world evidence, and regulatory engagement from the earliest stages of development. Insights from the obesity development community increasingly point to the need for more comprehensive evidence frameworks that better connect clinical outcomes with real-world patient benefit.

Recognizing these challenges, IQVIA has been actively participating in the DIA Obesity Consortium, a public-private partnership launched in September 2025 to improve the efficiency of obesity drug development, advance the assessment of quality weight loss, and evaluate obesity-related comorbidities. The consortium brings together regulators, industry leaders, clinicians, and patient advocacy organizations to address critical questions surrounding endpoints, trial design, and evidence generation that will shape the next generation of obesity therapies.

Through this collaborative effort, IQVIA is helping to advance the scientific and evidence-generation strategies needed to support a rapidly evolving obesity landscape, where success will increasingly depend on linking clinical efficacy with meaningful patient outcomes.

The Road Ahead

Although weight loss remains the primary endpoint accepted by regulators today, the conversation is evolving. Future obesity trials may increasingly incorporate measures of physical function, body composition, and patient experience to better reflect real-world outcomes that matter to patients and healthcare providers.

For biopharmaceutical companies, success will depend on designing studies capable of generating the evidence needed not only for regulatory approval, but also for differentiation in a rapidly expanding market. Organizations that invest today in innovative trial design, patient-centered endpoints, and robust evidence-generation strategies will be best positioned to lead the next chapter of obesity therapeutics.

As the obesity treatment paradigm continues to shift, now is the time to rethink how clinical benefit is measured and how evidence is generated.

Read the full DIA article: Obesity Drug Development: Time to Revisit Endpoints, Trial Design, and Evidence Generation.